AXIM Biotechnologies Inc. (OTCMKTS: AXIM) has finalized pre-clinical drug studies on the patent waiting for compound SPX-1009, showing malignant metastatic melanoma cells suppression. Dr. Douglas Lake’s lab at Arizona State University completed the independent research.
AXIM finalizes SPX-1009 studies
John W. Huemoeller II, AXIM Biotechnologies CEO, said, “We are extremely excited with the results of the in vitro testing. This potential therapeutic treatment could someday help control melanoma growth and metastasis with our compound SPX-1009 in a topical treatment.”
The study screened SPX-1009 in a cell-free enzymatic assay for the ability to suppress Quiescin Sulfhydryl oxidase I (QSOXI). QSOXI is a tumor-derived enzyme vital in cancer growth, metastasis, and invasion, which was tested for the ability to suppress invasion and growth of established A375 melanoma cell line and the low-passage patient der4eived melanoma. The study employed 3D tumor spheroid assays and 2D invasion assays to ascertain the compounds’ impact on tumor suppression.
The company’s next step is initiating animal studies to show SPX-1009’s ability to suppress metastasis and tumor growth in a murine melanoma model. In addition, the IP related to the SPX-1009 tech is subject to various patent-pending applications.
AXIM files for emergency approval for ImmunoPass
AXIM Biotechnologies recently announced that Empowered Diagnostics, its manufacturing partner, had filed an emergency approval for ImmunoPass. ImmunoPass is the company’s rapid test that measures COVID-19 neutralizing antibody levels to establish the presence of neutralizing antibodies in whole blood.
Huemoeller II said, “The COVID-19 pandemic itself is evidence that the world is interconnected. Because of that, it’s crucial that countries work together to resolve this global issue and have a consistent level of care in order to achieve relative normalcy as quickly as possible. In addition, ImmunoPass is incredibly easy to use and delivers accurate results in a matter of minutes, making it an ideal device for global use.”
AXIM Biotechnologies Inc. (OTCMKTS: AXIM) Offers Updates In SPX-1009 Compound And COVID-19 Neutralizing Antibodies Test
Post Views: 2 AXIM Biotechnologies Inc. (OTCMKTS: AXIM) has finalized pre-clinical drug studies on the patent waiting for compound SPX-1009,...
Planet 13 Holdings Inc. (OTCMKTS: PLNF) Adds Moxie to OC Superstore, Rubicon Organics Inc. (OTCMKTS: ROMJF) co-founds CCBC
Post Views: 2 Planet 13 Holdings Inc. (OTCMKTS: PLNF) has unveiled Moxie as its third store-in-store in the new Orange...
Heritage Cannabis Holdings Corp (OTCMKTS: HERTF) Posts A Robust Growth Of 338% YoY In Q2 2021: Achieves Success With RAD Branded Products
Post Views: 41 Heritage Cannabis Holdings Corp (OTCMKTS: HERTF) reported revenues of CAD 4.6 million (up 338% YoY) in Q2...
Net Savings Link Inc. (OTCMKTS: NSAV) Announce Launch of A Crypto Exchange and a Non-Fungible Token Resort
Post Views: 40 Net Savings Link Inc. (OTCMKTS: NSAV) has announced a collaboration with LABS Group to launch a community-owned...
Tauriga Sciences Inc. (OTCMKTS: TAUG) Announces Availability of Tauri Gum of Amazon.com
Post Views: 37 Tauriga Sciences Inc. (OTCMKTS: TAUG) has provided a shareholder update regarding its expected launch of limited editions...
Grow capital Inc. (OTCMKTS: GRWC), Cannabics Pharmaceutical Inc. (OTCMKTS: CNBX), and Surna Inc. (OTCMKTS: SRNA) Announce Management Appointments
Post Views: 40 Grow capital Inc. (OTCMKTS: GRWC) has announced the addition of two industry veterans to its wholly-owned subsidiary,...